Table 3 summarises the main characteristics and results of clinical studies conducted with our proposed immunotherapy in addition to anti-oestrogens and of clinical trials carried out with CDK 4/6 inhibitors in addition to AIs in first-line ER+, HER2- metastatic breast cancer patients. Here, ERBB2 is linked to breast cancer.